News

CTV coverage of The Conference Board of Canada Report on Canadian's access to arthritis medications. Features interviews with ambassador Darlene McPherson, who lives with RA, and Joanne Di Nardo, Arthritis Society Director of Public Policy & Government Affairs.

Physiology and pharmacology professor Frank Beier and chemistry professor Elizabeth Gillies have joined forces in a study developing a new treatment for arthritis sufferers. Beier and Gillies gained acknowledgement for their contributions by the Arthritis Society of Canada as one of the Top 10...

The Conference Board of Canada released a report today, funded by the Arthritis Society, titled Accessing Arthritis Medications—A Pan-Canadian Analysis. The analyses presented in this report show that patients’ access to and the cost of arthritis medications differ by jurisdiction and...

Patients must be at the table when creating a national pharmacare programTORONTO – Canadians face serious inequities in access and affordability to prescription medications depending on where they live and their access to employer-funded drug programs, says a report released today by The...

By combining wearable sensors with machine learning, Western Medical Biophysics and Surgery professor Matthew Teeter is helping patients with arthritis better understand their present conditions in order to have realistic expectations for life after surgery. Teeter was recently honoured by the...

Health and Senior Living Executive Trish Barbato Brings Focus on InnovationTORONTO – The Arthritis Society today announced the appointment of a new President and CEO to lead the organization into a new decade and further strengthen its efforts to support the six million Canadians living...

One of 14 new awards announced by the Arthritis Society, brings annual research commitment to nearly $4 millionDecember 18, 2019 – TORONTO – Back pain. It’s the #1 cause of disability worldwide, so odds are you’ve probably experienced it. If you’re lucky, it went...

Globe and Mail coverage of the Alberta biosimilars announcement, highlighting some (non-arthritis) patient groups' concerns.

The Alberta Government is changing coverage for biologics under the Alberta Drug Benefit List (ABDL). Public coverage for patients currently on certain originator biologics will be transitioned to biosimilars. This affects both patients who are new to biologics, and patients already receiving...